Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about sourcing Latanoprost for hair loss treatment. Users discuss potential sources and the difficulty of obtaining a prescription.

The user is experimenting with GHK-Cu and AHK-Cu to stop hair loss and promote hair growth, using a serum from Etsy and injectable GHK-Cu. They supplement this with dermastamping and ketoconazole shampoo.

A college student is embarrassed after their roommate found and mocked their hair loss medications, including Minoxidil and finasteride. The student is advised to report the privacy violation and consider finding a new roommate.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

The conversation discusses hair regrowth using oral minoxidil and RU58841, with visible baby hairs appearing after two months. One user questions the choice of RU58841 over finasteride.

The conversation is about an 18-year-old's progress with hair regrowth using oral Minoxidil, dermarolling, and RU58841 over three months, starting treatment after beginning to lose hair at 16. Participants are impressed with the improvement and encourage continued treatment.

A user shared their positive experience with a 2200 graft FUE hair transplant at DiStefano Hair Restoration in Worcester, MA, praising Dr. Heinis and his staff for their care. The user is also using oral Dutasteride, topical Minoxidil, and vitamins D and B.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.

The conversation discusses whether gt20029 could cure complete baldness, mentioning verteporfin as a realistic treatment. Other treatments like Minoxidil, finasteride, and RU58841 are implied to be less promising.

MaximusDurkimus shares experience with 0.25mg Finasteride, Minoxidil-induced lupus, and less than 10mg RU58841 for hair loss. Plans to try 0.025% topical Finasteride with 5% Stemoxydine and possibly Tretinoin, Fluridil, or CB-03-01 in the future.

The user is experiencing increased hair shedding while using finasteride and RU58841, possibly due to changes in application methods. They are considering adding minoxidil and stemoxydine to their regimen to improve results and manage hair greasiness.

First people receive Pyrilutamide on March 19th, 2022 for hair loss treatment. Users discuss obtaining the drug, its patent, and potential group buys.

The conversation discusses hair cloning progress and mentions treatments like Minoxidil, finasteride, and RU58841. Users also talk about hair transplants and their effectiveness.

Minoxidil, finasteride, and vitamins like D3K2 and beef liver are helping with hair regrowth, especially at the back of the head and temples. The user reports visible improvement with thicker hair and new baby hairs.

User shares link to conference about Pyrilutamide. Discussion includes phase 2 results, company's plans, and upcoming phase 3 trial.

The individual has been using minoxidil for beard growth for over two years, started oral minoxidil and dutasteride six months ago, and began RU58841 three months ago, which significantly enhanced their results. They are open to answering questions about their hair loss treatment experience.

KY19382, a promising compound for hair loss, is not widely discussed or used. One user is currently testing it and plans to share results in a few weeks.

The user is experiencing scalp irritation from using RU58841 with a 70% ethanol and 30% propylene glycol vehicle and is considering switching to a less irritating vehicle, such as 30% ethanol with 70% squalane or emu oil. They are seeking feedback on the effectiveness and irritation levels of these alternative carriers.

Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. User questions effectiveness of Redensyl.

The user wants to mix 0.2 ml of RU58841 solution with 2 ml of Alfatradiol to use 10 mg of RU58841 daily due to concerns about side effects. They are asking if this combination would be effective for hair loss treatment.

The conversation is about hair loss treatments, specifically the anticipation for the release of a new treatment, GT20029, by 2028. Users are discussing their experiences with current treatments like finasteride and dutasteride, and the potential of future treatments, including FAK inhibitors and verteporfin trials.

A 29-year-old male shares his hair loss treatment progress using dutasteride, minoxidil, dermastamping, and ketoconazole shampoo, while discontinuing RU58841 due to side effects. He is hopeful for hair recovery to consider a hair transplant and discusses potential side effects and experiences with other users.

User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.

PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.

The user feels insecure about hair loss and is seeking affordable solutions, as hair transplants are too expensive. They are looking for advice on treatments like Minoxidil, finasteride, or RU58841.

Rosemary-lavender oil can stimulate hair growth compared to a placebo. Some users combine it with treatments like dutasteride, minoxidil, and RU58841.

The user is seeking advice on which treatment to add to their current regimen for male pattern baldness. They have previously tried Dutasteride, Nizoral, and oral Minoxidil, but experienced continued hair loss. They are specifically asking for experiences with RU58841, Stemoxydine, or Alfatradiol.

Setipiprant and bimatoprost are being discussed as potential future treatments for hair loss. Some individuals have started testing setipiprant before FDA approval, but no progress updates are available yet.

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.